Clinical Trials
3
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2019
Active, not recruiting
1
33.3%
Enrolling By Invitation
1
33.3%
Recruiting
1
33.3%
No approval data available
- The FDA has cleared Prime Medicine's IND for PM647, an investigational in vivo Prime Editor designed to correct the E342K (Pi*Z) mutation in SERPINA1 in alpha-1 antitrypsin deficiency. - A global Phase 1/2 first-in-human trial will test ascending doses of a one-time intravenous infusion, initially enrolling adults with lung-only AATD before expanding to a liver disease cohort. - In fully humanized mouse models, PM647 achieved high editing efficiency and restored corrected M-AAT protein into the healthy human range at clinically relevant doses with a single infusion. - PM647 uses the same liver-directed lipid nanoparticle as PM577a, Prime Medicine's Wilson disease program, and initial clinical data are expected in 2027.
- Prime Medicine prevailed over Beam Therapeutics in a patent dispute, a development that strengthens its intellectual property position in the gene editing field. - The company is approaching its first clinical entry, with analysts noting Prime Medicine is "soon in the clinic" for its prime editing programs. - Both Prime Medicine and Beam Therapeutics remain considered investable by analysts despite the competitive and legal landscape. - The developments underscore Prime Medicine's progress in advancing its prime editing platform toward therapeutic applications.
- An arbitration panel ruled in favor of Prime Medicine, determining the company does not owe Beam Therapeutics monetary damages in a dispute over rival AATD gene editing therapies. - Both companies originated from David Liu's labs and entered a 2019 collaboration that Beam claimed Prime breached by advancing its own AATD treatment. - Prime's prime editing therapy for AATD is in preclinical testing and could produce initial human data next year, while Beam's base editing treatment is in advanced clinical development. - Beam stated it "respectfully disagrees" with aspects of the ruling but acknowledged the decision does not affect its broader exclusive rights to certain prime editing tools.
- The global gene editing therapeutics market is projected to grow at a compound annual growth rate of 12.5%, fueled by expanding clinical applications and rising disease burden. - CRISPR-based technologies dominate the market due to their efficiency and cost-effectiveness, while oncology represents the largest therapeutic application segment. - High development costs, regulatory complexity, and off-target safety concerns remain significant barriers to broader adoption and commercialization. - Key players including CRISPR Therapeutics, Intellia Therapeutics, Editas Medicine, and Beam Therapeutics are driving innovation through partnerships and investments in next-generation editing platforms.
- The U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, Prime Medicine's investigational Prime Edited hematopoietic stem cell therapy for p47phox-deficient CGD. - The designation was based on Phase 1/2 clinical data published in The New England Journal of Medicine showing rapid engraftment and durable restoration of immune cell function with a single dose. - PM359 now holds four FDA designations: RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease, underscoring the serious unmet need in CGD. - RMAT status enables intensive FDA engagement, eligibility for rolling and priority BLA review, and discussions on surrogate endpoints that may support accelerated approval.
- Ty Sperle, a 19-year-old from British Columbia, became the first person in the world to be cured of chronic granulomatous disease through prime editing gene therapy in a breakthrough clinical trial. - The treatment involved extracting Sperle's own cells, correcting the genetic "spelling mistake," and reinfusing them back into his body where they multiplied and restored proper immune function. - The successful cure eliminates Sperle's need for daily antibiotics and antifungal medications while removing the constant threat of life-threatening infections that characterize this rare genetic condition. - The results, published in the New England Journal of Medicine, represent a significant advancement in gene editing technology and offer hope for treating other rare genetic diseases.
- Prime Medicine published Phase 1/2 clinical data for PM359 in the New England Journal of Medicine, marking the first-in-human demonstration of Prime Editing safety and efficacy for chronic granulomatous disease treatment. - Two patients achieved rapid neutrophil engraftment with 69% and 83% dihydrorhodamine-positive neutrophils by Day 30, far exceeding the 20% minimum threshold for clinical benefit. - Both patients experienced durable restoration of NADPH oxidase activity and early clinical benefits, including resolution of CGD-associated colitis symptoms, without any safety concerns attributable to PM359. - The results support Prime Editing's potential advantages over other gene editing technologies, as it does not induce double-strand breaks and may be better tolerated by hematopoietic stem cells.
- Medera Inc. announced the appointment of three senior executives to strengthen its leadership team as the company advances its cardiac gene therapy programs through ongoing clinical trials. - The new appointments include Fubao Wang, Ph.D., as Chief Regulatory Officer and Chief Technical Officer at Sardocor, bringing over 28 years of pharmaceutical and biotech experience across gene therapy and regulatory affairs. - James Kim joins as Chief Corporate Officer with over 20 years of biopharmaceutical industry experience, having executed over 100 transactions totaling approximately $25 billion in financings and M&A deals. - Niharika Kamat, M.S., was appointed Vice President of Clinical Operations at Sardocor, bringing nearly 20 years of experience in global Phase 1-3 trials across cardiovascular and rare disease indications.
- Septerna has appointed Keith Gottesdiener, M.D., a veteran biotechnology executive with over 30 years of experience, to its board of directors and as chairperson of a newly constituted R&D Committee. - Dr. Gottesdiener brings extensive leadership experience from Prime Medicine, Rhythm Pharmaceuticals, and Merck Research Laboratories, where he oversaw the approval of more than 20 novel therapeutics. - The appointment comes at a pivotal time as Septerna advances its GPCR-targeted drug pipeline, including the promising PTH1R program for hypoparathyroidism. - Septerna's proprietary Native Complex Platform™ enables novel approaches to GPCR drug discovery and has led to a diverse pipeline of oral small molecule drug candidates.
- The Cystic Fibrosis Foundation has committed up to $24 million in additional funding to Prime Medicine to advance prime editing gene therapy for cystic fibrosis patients. - The funding will focus on developing a prime editing therapy targeting the G542X nonsense mutation, one of the most prevalent CF-causing mutations with no available treatments. - Prime Medicine's prime editing technology has the potential to permanently correct CFTR gene mutations and could eventually treat the vast majority of people with cystic fibrosis. - The company is investigating multiple approaches including hotspot editing and PASSIGE technology to address various CF mutations through a single platform.
